Literature DB >> 378855

Capsular serotypic specificity of the protection conferred on mice by Klebsiella pneumoniae ribosomal preparations.

M Riottot, J M Fournier, J Pillot.   

Abstract

Klebsiella pneumoniae ribosomal preparations protect mice immunized by the subcutaneous route against an intraperitoneal challenge of 100 50% lethal doses. The minimal protective doses are 5 and 0.4 micrograms of proteins for preparations extracted from strains of capsular serotypes 1 and 2, respectively. This difference in protective activity is also found in bacteria killed by Formalin. The protective activity of these preparations is not diminished by their purification on sucrose gradient, which eliminates most of the membrane vesicles which are visible by electron microscopy. The use of four strains of K. pneumoniae belonging to capsular serotypes 1 and 2 allowed us to show that the immunoprotective capacity of the ribosomal preparations was specific to the capsular serotype of the origin strain. This was confirmed by experiments in which the serum of immunized mice was transferred passively. The experimental data favor the presence in the ribosomal preparation of antigens belonging to the bacterial surface and resisting elimination by ultracentrifugation on sucrose gradient. Those surface antigens (possibly capsular polysaccharide) at least play a role in the orientation of the specificity of the protection induced by the ribosomal preparations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 378855      PMCID: PMC414326          DOI: 10.1128/iai.24.2.476-482.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Biological properties of an immunogenic pneumococcal subcellular preparation.

Authors:  H C Thompson; T K Eisenstein
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

2.  Evidence for an extrinsic immunogen in effective ribosomal vaccines from Salmonella typhimurium.

Authors:  P Hoops; N E Prather; J Berry; J M Ravel
Journal:  Infect Immun       Date:  1976-04       Impact factor: 3.441

3.  Humoral immunity to Streptococcus pneumoniae induced by a pneumococcal ribosomal protein fraction.

Authors:  C L Swendsen; W Johnson
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

4.  Characterization of the immunoprotective antigen of ribosomal preparations from Haemophilus influenzae.

Authors:  R P Tewari; M Lynn; A J Birnbaum; M Solotorovsky
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

5.  Immunoprotective activity of ribosomes from Haemophilus influenzae.

Authors:  M Lynn; R P Tewari; M Solotorovsky
Journal:  Infect Immun       Date:  1977-02       Impact factor: 3.441

Review 6.  Microbial surfaces in relation to pathogenicity.

Authors:  H Smith
Journal:  Bacteriol Rev       Date:  1977-06

7.  Direct evidence for the presence of lipopolysaccharide components in Pseudomonas ribosomal vaccine.

Authors:  M M Lieberman
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

8.  Evidence for O antigens as the antigenic determinants in "ribosomal" vaccines prepared from Salmonella.

Authors:  T K Eisenstein
Journal:  Infect Immun       Date:  1975-08       Impact factor: 3.441

9.  Role of endotoxin contamination in ribiosomal vaccines prepared from Salmonella typhimurium.

Authors:  M L Misfeldt; W Johnson
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

10.  Immunogenicity of ribosomal vaccines isolated from group A, type 14 Streptococcus pyogenes.

Authors:  W O Schalla; W Johnson
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

View more
  10 in total

1.  Immunogenic properties of Klebsiella pneumoniae type 2 capsular polysaccharide.

Authors:  A Robert; H Jouin; J M Fournier
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

2.  Protection against fatal Klebsiella pneumoniae burn wound sepsis by passive transfer of anticapsular polysaccharide.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

Review 3.  Progress in immunization against Klebsiella infections.

Authors:  S J Cryz
Journal:  Eur J Clin Microbiol       Date:  1983-12       Impact factor: 3.267

4.  Immunoprotective activity of capsular polysaccharide in Klebsiella pneumoniae ribosomal preparations does not involve ribonucleic acid.

Authors:  M M Riottot; J M Fournier
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

5.  Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fractions.

Authors:  R Levy; E Segal; E Eylan
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

6.  Murine immunoprotective activity of Klebsiella pneumoniae cell surface preparations: comparative study with ribosomal preparations.

Authors:  J M Fournier; C Jolivet-Reynaud; M M Riottot; H Jouin
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

7.  Direct evidence for the involvement of capsular polysaccharide in the immunoprotective activity of Klebsiella pneumoniae ribosomal preparations.

Authors:  M M Riottot; J M Fournier; H Jouin
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

8.  Experimental Klebsiella septicemia in mice: treatment with specific antibodies from the rabbit alone and in combination with gentamicin.

Authors:  M Trautmann; Y Müller-Leutloff; T Hofstaetter; F R Seiler; H Hahn
Journal:  Infection       Date:  1985 Jan-Feb       Impact factor: 3.553

9.  Analysis of cell wall and membrane contamination of ribosomal preparations from Streptococcus mutans.

Authors:  R L Gregory; I L Shechmeister
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

10.  Evaluation of Recombinant Multi-Epitope Outer Membrane Protein-Based Klebsiella pneumoniae Subunit Vaccine in Mouse Model.

Authors:  Litty Babu; Siva R Uppalapati; Murali H Sripathy; Prakash N Reddy
Journal:  Front Microbiol       Date:  2017-09-20       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.